CJC-1295 Dosage: Study Amounts Aren’t Personal Advice
The Short Version: Testing Hasn’t Chosen an Amount for You
CJC-1295 is a compound tested by shot for growth hormone release. Here you'll learn why study amounts can't guide your care.
The brief human CJC-1295 trials used the form with DAC, its added part. Teichman's 2006 study used 30, 60, 90, and 125 micrograms per kilogram of each volunteer's body weight [1].
Each microgram is one of a million equal parts of a gram. Ionescu and Frohman's 2006 study used 60 and 90 micrograms per kilogram [2].
Those CJC-1295 figures come from testing, rather than an amount chosen for your health. No published human study measures how CJC-1295 without DAC leaves blood.
That shorter-lasting form also has the name Mod GRF 1-29. You can't use findings about one form to establish the other form's safety.
Alba's 2006 study involved mice missing the hormone that prompts growth hormone release. The mice received 2 micrograms daily throughout five weeks [4].
Separate rat studies tested ipamorelin, another compound that prompts growth hormone release [10][11]. The rats received 0.5–100 micrograms per kilogram two to three times daily.
I'd ask your doctor what evidence applies to your reason for seeking care. Animal and healthy-volunteer findings don't establish your treatment amount.
Joining a Blood Protein Protects the Longer-Lasting Form
The shorter-lasting CJC-1295 form lacks published human measurements of its time in blood. Jetté's 2005 lab work supports an estimate of about 30 minutes for half to leave [3].
Teichman's 2006 human study measured the longer-lasting form instead [1]. Albumin, a blood protein that carries other substances, attaches to the added DAC part on CJC-1295.
Labs list about 70 kilodaltons for the joined pair, using weight units much smaller than a gram. What matters for you is that the larger pair is harder for the kidneys to remove quickly.
The added protein also helps prevent breakdown inside the body. The roughly 250-fold difference in time doesn't prove either form would help you more.
Sermorelin, another compound that prompts growth hormone release, lacks the same protection. Half the sermorelin leaves blood in about 10–12 minutes [15].
CJC-1295 Forms Haven’t Been Compared for Health Results
No human study has tested the forms against each other for benefits and safety. You can't pick a better form from time in blood alone.
Teichman's 2006 testing used single shots of the longer-lasting CJC-1295 form [1]. Later research used weekly shots or shots spaced two weeks apart because hormone levels stayed higher.
Those choices explain how researchers arranged testing, rather than a schedule for your care. Keeping a hormone raised longer doesn't establish better health or fewer problems.
The shorter-lasting form is also called Mod GRF 1-29. Its estimate of about 30 minutes for half to leave blood comes from lab work, leaving the timing in people unknown.
Researchers use more frequent shots when studying that form's expected brief response. Each shot is expected to cause a burst fading over one to two hours.
The DAC form keeps the hormone level higher between the body's usual bursts [14]. Studies comparing the forms in people haven't shown how that difference could change your health.
You can ask which form has actually been tested for your concern. Ask whether testing measured a health change or only a blood-test number.
Your doctor needs your medical history before discussing any proposed treatment. You can ask which visits and blood tests would be needed, how much time those checks would take, and what the full course of care would cost you over time.
Human Testing Leaves Shot Timing Unsettled
Studies of the longer-lasting CJC-1295 form used single, weekly, or every-other-week shots [1][2]. Half the compound takes about 6–8 days to leave blood, which explains those research choices.
The shorter-lasting form, Mod GRF 1-29, has only a lab estimate of its time in blood. That 30-minute estimate explains more frequent CJC-1295 study shots; the timing in people remains unknown.
Published human testing ranged from a single shot to repeated use over a 49-day period. No human comparison has tested 5 days with shots followed by 2 days off against use without breaks.
Some testing also gave CJC-1295 before meals to limit changes caused by food. Insulin, the hormone that helps control blood sugar, and higher sugar levels can weaken growth hormone release.
Jetté 2005 and Teichman 2006 describe that reason for testing before eating [1][3]. Those study choices don't give you an amount or timing plan for treatment.
Claims About Longer Use Don’t Establish Safe Breaks
Descriptions of CJC-1295 use mention 12 weeks or more and five days with shots followed by two days off. Those descriptions aren't backed here by a named human trial comparing breaks with no breaks.
People in the Teichman 2006 trial were followed for at most 49 days [1][4]. Alba's mouse study lasted five weeks without breaks, so it can't settle the question for you.
Descriptions of four to twelve weeks don't establish published human follow-up of that length. Longer-use accounts mainly come from pharmacies describing care, without published trials that other scientists have checked.
Those accounts haven't compared people taking breaks with people using the compound without breaks. You don't have a tested length of safe use to rely on.
People may call a planned break a cycle. Testing hasn't settled whether such breaks help, how long breaks might last, or whether breaks are needed.
Mixed Peptides Need Separate Storage Checks
Reconstituted peptide stability data for CJC-1295 in bacteriostatic water (BAC water) is not directly published for this compound. General peptide stability literature supports refrigerated storage at 2–8°C for up to approximately 30 days post-reconstitution for peptides of comparable size and structure. Freeze-thaw cycles risk peptide bond degradation and are generally avoided in laboratory protocols. The with-DAC albumin conjugate gains additional stability post-injection, but reconstituted-vial stability is a pre-injection concern separate from in vivo pharmacokinetics.
For CJC-1295, reconstitution instructions and clinical access belong to separate records: Promise Peptides (mypromise.com) operates within clinician-led telehealth, where prescription-only care requires evaluation by a licensed prescriber rather than extrapolation from laboratory handling notes.
Food Can Weaken the Growth Hormone Rise Being Measured
Food can change growth hormone release, which makes blood-test comparisons harder. Insulin, a hormone that helps control blood sugar, and higher sugar levels can weaken the gland's response.
Jetté 2005 and Teichman 2006 explain why CJC-1295 was tested before eating [1][3]. Limiting the effects of meals helped researchers measure the compound's hormone response more clearly.
That choice makes study results easier to compare, but doesn't choose treatment timing for you. Ask your doctor whether a claim concerns testing conditions or a measured health benefit.
